Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

The startup claims that, unlike injectable drugs such as Ozempic and Mounjaro, which can have side effects, its solution is a ...

Colonic air insufflation averaged 30 bulb compressions. Thirty-three patients received IV glucagon (1 mg), and 27 patients did not. The colon was divided into eight segments, and the adequacy of ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

Study underscores the direct vascular effects of this class of drugs, researchers say AURORA, CO / ACCESS Newswire / March 29, 2025 / A novel study of a semaglutide, a glucagon-like peptide-1 (GLP-1) ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist ... once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care.